These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28484975)

  • 1. A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.
    Yoshikado T; Maeda K; Furihata S; Terashima H; Nakayama T; Ishigame K; Tsunemoto K; Kusuhara H; Furihata KI; Sugiyama Y
    Pharm Res; 2017 Aug; 34(8):1570-1583. PubMed ID: 28484975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.
    Maeda K; Ikeda Y; Fujita T; Yoshida K; Azuma Y; Haruyama Y; Yamane N; Kumagai Y; Sugiyama Y
    Clin Pharmacol Ther; 2011 Oct; 90(4):575-81. PubMed ID: 21832990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.
    Higgins JW; Ke AB; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2014 Nov; 42(11):1780-4. PubMed ID: 25106415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
    Yoshikado T
    Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
    Treiber A; Schneiter R; Häusler S; Stieger B
    Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
    Markert C; Schweizer Y; Hellwig R; Wirsching T; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Br J Clin Pharmacol; 2014 Jan; 77(1):141-8. PubMed ID: 23738582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T; Hisaka A; Sugiyama Y; Ito K
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.
    Varma MV; Kimoto E; Scialis R; Bi Y; Lin J; Eng H; Kalgutkar AS; El-Kattan AF; Rodrigues AD; Tremaine LM
    Clin Pharmacol Ther; 2017 Mar; 101(3):406-415. PubMed ID: 27648490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
    Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
    AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
    Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
    J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor.
    Imaoka T; Mikkaichi T; Abe K; Hirouchi M; Okudaira N; Izumi T
    Drug Metab Dispos; 2013 Jul; 41(7):1442-9. PubMed ID: 23640987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
    Prueksaritanont T; Tatosian DA; Chu X; Railkar R; Evers R; Chavez-Eng C; Lutz R; Zeng W; Yabut J; Chan GH; Cai X; Latham AH; Hehman J; Stypinski D; Brejda J; Zhou C; Thornton B; Bateman KP; Fraser I; Stoch SA
    Clin Pharmacol Ther; 2017 Apr; 101(4):519-530. PubMed ID: 27943276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions.
    Nishizawa K; Nakanishi T; Tamai I
    Drug Metab Dispos; 2017 Feb; 45(2):224-227. PubMed ID: 27934638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.
    Asaumi R; Toshimoto K; Tobe Y; Hashizume K; Nunoya KI; Imawaka H; Lee W; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):186-196. PubMed ID: 29368402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model.
    Storelli F; Ladumor MK; Liang X; Lai Y; Chothe PP; Enogieru OJ; Evers R; Unadkat JD
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):118-131. PubMed ID: 37833845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics.
    Sato M; Toshimoto K; Tomaru A; Yoshikado T; Tanaka Y; Hisaka A; Lee W; Sugiyama Y
    Drug Metab Dispos; 2018 May; 46(5):740-748. PubMed ID: 29475833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.